Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quanterix Corporation filings document the regulatory record of a life sciences company built around ultra-sensitive biomarker instruments, consumables, assay services, and clinical laboratory testing. Its Form 8-K disclosures include operating and financial results, material-event reports, clinical or regulatory disclosures, capital-structure items, and leadership or board changes.
Proxy materials for QTRX describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, equity incentive plan approvals, and governance provisions. The filing record also covers shareholder voting results and charter-related governance matters, providing formal disclosure of the company’s board structure, compensation framework, ownership voting mechanics, and public-company controls.
Quanterix Corp Chief Financial Officer Vandana Sriram reported routine equity compensation activity involving restricted stock units. On June 15, 2026, restricted stock units converted into 1,833 shares of common stock, and 548 shares were withheld at $3.10 per share to cover tax obligations.
These transactions reflect RSU vesting and related tax-withholding dispositions, not open-market trades. Following the transactions, Sriram directly owns 30,261 shares of Quanterix common stock. Footnotes state RSUs convert one-for-one into common stock and describe multi-year vesting schedules for prior RSU grants.
Quanterix Corp Chief Financial Officer Jason F. Faessler has filed an initial Form 3, which is the first statement of his beneficial ownership as an insider. The filing reports no transactions in Quanterix stock and no option exercises or other activity in this excerpt.
Quanterix Corp Chief Technology Officer Michael Francis Miller reported routine equity compensation activity on June 15, 2026. He exercised derivative awards for a total of 1,558 common shares and used 467 shares, valued at $3.10 each, to cover tax obligations. Following these transactions, he directly holds 33,851 shares of common stock, and restricted stock units continue to vest over time under previously granted awards.
Quanterix Corp Chief Commercial Officer Benjamin Meadows reported an open-market purchase of company stock. On May 12, 2026, he bought 3,500 shares of Common Stock at a price of $2.77 per share. Following this transaction, he directly holds 3,500 shares of Quanterix common stock.
Quanterix Corp filed an initial ownership report for Chief Commercial Officer Benjamin Meadows, outlining his equity-based compensation. Meadows holds 76,234 stock options with an exercise price of $5.88 per share, expiring on October 6, 2035, vesting 25% after one year and the rest in 36 monthly installments.
He was granted 22,959 restricted stock units on October 6, 2025 with 25% vesting after one year and the remaining 75% in 36 monthly installments. On February 15, 2026, he received 70,223 restricted stock units vesting 25% per year for four years, and 70,223 performance stock units that may vest in four equal annual installments once performance conditions under the 2026 Employee Equity Guidelines are met.
Quanterix Corporation reported the results of its 2026 annual shareholder meeting held on June 9, 2026. Stockholders elected William P. Donnelly and Ivana Magovčević-Liebisch, Ph.D., J.D. as independent directors for one-year terms and approved the advisory vote on executive compensation.
Shareholders also ratified KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. However, they did not approve an amendment and restatement of the 2017 Employee, Director and Consultant Equity Incentive Plan that would have extended the plan through June 9, 2031.
Quanterix Corporation has appointed Jason Faessler as its new Chief Financial Officer and Treasurer, with employment expected to begin on June 22, 2026. He brings senior finance leadership experience from Bruker Corporation, PAREXEL, EMC and Harvard Business Publishing, with a background in strategic planning and operational finance.
Under an employment agreement dated May 31, 2026, Faessler will receive an initial annual base salary of $475,000, a $200,000 cash sign-on bonus, and is eligible for an annual performance bonus targeted at up to 50% of base salary. He will also receive restricted stock units equal to 0.30% of Quanterix’s outstanding common shares on his start date, vesting in four equal annual installments.
If his employment is terminated without Cause or he resigns for Good Reason, Faessler is entitled to 12 months of base salary continuation, a pro-rated target bonus, and subsidized health benefits. If such a termination occurs in connection with a Change-in-Control, he also receives full vesting of outstanding unvested equity awards.
Quanterix Corp’s Chief Technology Officer Michael Francis Miller reported compensation-related equity transactions, not open-market trades. He exercised restricted stock units (RSUs) that converted into 130 shares of common stock, then 39 of those shares were disposed of to cover tax obligations.
After these transactions, he directly holds 33,834 shares of common stock and 419 RSUs. The RSUs were granted on September 23, 2022 and vest over four years, with 25% on the first anniversary and the remaining 75% in 36 equal monthly installments.
Quanterix Corporation appointed Anthony Catalano as its new Chief Operating Officer effective May 14, 2026. He brings prior leadership experience from Flagship Pioneering, Akoya Biosciences, Bruker Cellular Analysis and Revvity.
Under his employment agreement, Catalano will receive a $400,000 annual base salary, a $50,000 cash sign-on bonus and eligibility for an annual performance bonus targeted at up to 50% of base salary. He also received restricted stock units equal to 0.30% of Quanterix common shares outstanding on his start date, vesting in four equal annual installments.
If the company terminates him without Cause or he resigns for Good Reason, he is entitled to six months of base salary continuation, a pro-rated target bonus for the year of termination and subsidized health benefits. If such a termination occurs in connection with a Change-in-Control, salary continuation extends to nine months and all outstanding time-based equity awards become fully vested. Michael Miller, the former Chief Operating Officer, has moved to the role of Chief Technology and Products Officer.
Quanterix Corp Chief Financial Officer Vandana Sriram reported routine equity compensation activity involving restricted stock units (RSUs). On May 15, 2026, RSUs converted into common stock in several tranches, including 1,056, 514, and 263 shares, reflecting scheduled vesting.
To cover tax obligations, the filing shows share dispositions of 315, 154, and 79 shares of common stock at $2.75 per share, characterized as tax-withholding transactions rather than open-market sales. Following these transactions, the CFO directly held 28,897 shares of Quanterix common stock, while additional RSUs remain outstanding and continue to vest over time.